Promising outlook with sugemalimab in non-small-cell lung cancer

Affiliations

¹ Laboratory of Molecular Biology, Institut d'Invesigació en Ciències de la Salut Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China; Zhenjiang Hospital of Chinese Traditional and Western Medicine, Zhenjiang, China. Electronic address: cao_peng@njucm.edu.cn.

Comment

Rafael Rosell et al. Lancet Oncol. 2022 Feb.

. 2022 Feb;23(2):186-188.

doi: 10.1016/S1470-2045(21)00698-7. Epub 2022 Jan 14.

¹ Laboratory of Molecular Biology, Institut d'Invesigació en Ciències de la Salut Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China; Zhenjiang Hospital of Chinese Traditional and Western Medicine, Zhenjiang, China. Electronic address: cao_peng@njucm.edu.cn.

No abstract available

Conflict of interest statement

We declare no competing interests.

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Zhou Q, et al. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038429 Clinical Trial.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Zhou C, et al. Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038432 Clinical Trial.